HHealthcare Read More NewLimit ‘close’ to clinic-ready epigenetic reprogramming therapyNovember 27, 2025 Liver rejuvenation program produces a ‘lead payload’ as biotech begins its journey towards human clinical trials. After several…
HHealthcare Read More Lilly invests in epigenetic reprogramming biotechOctober 22, 2025 NewLimit adds $45m in new funding at a $1.6bn valuation following preclinical progress that brings clinical trials closer…